RT Journal Article
SR Electronic
T1 The impact of substance use on tuberculosis treatment adherence among tuberculosis patients in Limpopo Province, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.08.23291161
DO 10.1101/2023.06.08.23291161
A1 Matakanye, Hulisani
A1 Tshitangano, Takalani
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.08.23291161.abstract
AB Background Substance use are associated with high discontinuation of tuberculosis treatment which is a barrier to tuberculosis control. Treatment discontinuation significantly increase the risk of poor treatment outcomes in both drug-susceptible and multidrug-resistant tuberculosis patients. This study aimed to explore the impact of substance use on tuberculosis treatment adherence among tuberculosis patients in Limpopo Province, South Africa.Method The study employed exploratory qualitative research design. Purposive sampling method was used to sample eight TB focal person and eight facility operational managers who were working in eight community health center within three selected districts in Limpopo province. Data were collected through key informant in-depth interviews and were analysed using Colaizzi’s method.Results The study results show four individual major themes that emerged from data analysis: (1) Patients forget to take treatment, (2) Patients miss follow up visit and DOT support appointments (3) Patients refuse social support (4) Patients refuse to attend health education and counselling.Conclusion The study highlighted serious impact of substance abuse on TB treatment adherence among TB patients. There is a need to integrate treatment for alcoholism and illicit drug users into primary health care to identify specific group of patients suffering from alcoholism and drug addiction on time, as a component of comprehensive TB treatment strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The proposal was submitted and presented to the School of Health Science and the University Higher Degrees Committee (UHDC), and an ethical clearance was granted (SHS/19/PH/28/0411).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAuthors do not have permission to share raw data publicly to maintain confidentiality. Permission to collect data was granted by Provincial Department of health and the researcher agreed not to share raw data with any third person as they were meant specifically for the research project. Participants signed written informed consent form and were assured that data will be confidential and will only be used for the purpose of the study. Analyzed data is available from the researcher with meaningful request.